valproate-induced weight gain
Significant weight increase associated with valproate therapy, occurring in up to 50% of patients and potentially leading to metabolic complications.
Full Definition
Valproate-induced weight gain is a common and clinically significant adverse effect occurring in 40-50% of patients treated with valproate or divalproex sodium. The mechanism involves multiple factors including increased appetite, altered glucose metabolism, insulin resistance, and direct effects on adipose tissue. Weight gain typically begins within the first few months of treatment and can be substantial, with some patients gaining 10-20 pounds or more. This effect appears to be dose-related and more pronounced in certain populations, including women with epilepsy or bipolar disorder. The weight gain is often associated with the development of metabolic syndrome, including insulin resistance, dyslipidemia, and increased cardiovascular risk. Management strategies include dietary counseling, exercise programs, and in some cases, consideration of alternative mood stabilizers. The weight gain is generally not reversible with dose reduction and may persist even after discontinuation.
Usage
Usage note: Always specify the medication form (valproate vs. divalproex) and quantify weight changes when possible; consider metabolic monitoring recommendations.
In Context
- "The patient experienced significant valproate-induced weight gain, prompting consideration of alternative mood stabilizer options." — Treatment review note
- "Baseline weight and metabolic parameters should be established before initiating valproate to monitor for weight gain." — Prescribing protocol